UBS Group
TVRD

UBS Group’s Tvardi Therapeutics TVRD Stock Holding History

UBS Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160K Buy
50,454
+14,899
+42% +$58.4K ﹤0.01% 6759
2025
Q4 		$153K Sell
35,555
-12,924
-27% -$116K ﹤0.01% 6709
2025
Q3 		$1.89M Buy
48,479
+19,126
+65% +$545K ﹤0.01% 5009
2025
Q2 		$685K Buy
29,353
+22,986
+361% +$544K ﹤0.01% 5754
2025
Q1 		$96.8K Buy
6,367
+3,673
+136% +$55.4K ﹤0.01% 7071
2024
Q4 		$49.5K Buy
2,694
+2,642
+5,081% +$28.8K ﹤0.01% 7303
2024
Q3 		$577 Sell
52
-1,977
-97% -$23.2K ﹤0.01% 8881
2024
Q2 		$18.8K Buy
2,029
+600
+42% +$14.3K ﹤0.01% 7338
2024
Q1 		$46.8K Buy
1,429
+417
+41% +$10.8K ﹤0.01% 6538
2023
Q4 		$27.1K Buy
1,012
+318
+46% +$13.2K ﹤0.01% 6910
2023
Q3 		$42K Sell
694
-310
-31% -$29.1K ﹤0.01% 6410
2023
Q2 		$102K Sell
1,004
-74
-7% -$10.2K ﹤0.01% 5994
2023
Q1 		$191K Sell
1,078
-602
-36% -$202K ﹤0.01% 5416
2022
Q4 		$649K Buy
1,680
+1,252
+293% +$476K ﹤0.01% 4462
2022
Q3 		$144K Buy
428
+156
+57% +$56.5K ﹤0.01% 5397
2022
Q2 		$90K Sell
272
-166
-38% -$58.2K ﹤0.01% 5511
2022
Q1 		$192K Sell
438
-594
-58% -$244K ﹤0.01% 5404
2021
Q4 		$452K Buy
1,032
+676
+190% +$340K ﹤0.01% 5058
2021
Q3 		$198K Sell
356
-260
-42% -$130K ﹤0.01% 5322
2021
Q2 		$317K Buy
616
+94
+18% +$59.6K ﹤0.01% 5045
2021
Q1 		$408K Sell
522
-248
-32% -$170K ﹤0.01% 5023
2020
Q4 		$419K Buy
770
+196
+34% +$103K ﹤0.01% 4741
2020
Q3 		$262K Sell
574
-353
-38% -$205K ﹤0.01% 4630
2020
Q2 		$571K Sell
927
-203
-18% -$112K ﹤0.01% 4027
2020
Q1 		$538K Sell
1,130
-1,186
-51% -$644K ﹤0.01% 3899
2019
Q4 		$1.34M Buy
2,316
+774
+50% +$543K ﹤0.01% 3940
2019
Q3 		$1.01M Sell
1,542
-934
-38% -$776K ﹤0.01% 3956
2019
Q2 		$1.92M Buy
2,476
+621
+33% +$436K ﹤0.01% 3185
2019
Q1 		$1.31M Sell
1,855
-3,797
-67% -$2.27M ﹤0.01% 3357
2018
Q4 		$2.64M Buy
5,652
+3,859
+215% +$2.49M ﹤0.01% 2749
2018
Q3 		$1.55M Buy
1,793
+1,313
+274% +$948K ﹤0.01% 3453
2018
Q2 		$332K Sell
480
-4,472
-90% -$2.27M ﹤0.01% 4615
2018
Q1 		$2.21M Buy
4,952
+3,874
+359% +$1.88M ﹤0.01% 3050
2017
Q4 		$475K Sell
1,078
-2,004
-65% -$914K ﹤0.01% 4332
2017
Q3 		$1.52M Buy
3,082
+2,616
+561% +$1.31M ﹤0.01% 3355
2017
Q2 		$258K Buy
466
+173
+59% +$110K ﹤0.01% 4579
2017
Q1 		$194K Buy
293
+43
+17% +$23K ﹤0.01% 4663
2016
Q4 		$84K Buy
250
+221
+762% +$70.9K ﹤0.01% 5419
2016
Q3 		$9K Sell
29
-40
-58% -$8.67K ﹤0.01% 6856
2016
Q2 		$12K Buy
69
+55
+393% +$12K ﹤0.01% 6686
2016
Q1 		$3K Sell
14
-54
-79% -$16.1K ﹤0.01% 7215
2015
Q4 		$41K Sell
68
-38
-36% -$20.9K ﹤0.01% 6007
2015
Q3 		$55K Buy
106
+58
+121% +$38.8K ﹤0.01% 5761
2015
Q2 		$21K Buy
48
+34
+243% +$13.1K ﹤0.01% 6836
2015
Q1 		$5K Hold
14
– – ﹤0.01% 8126
2014
Q4 		$5K Buy
+14
New +$4.51K ﹤0.01% 9010

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

UBS Group's TVRD Position: Q1 2026 in Review

UBS Group increased its Tvardi Therapeutics (TVRD) stake by 42% in Q1 2026, buying an estimated $58.4K and bringing the position to 50,454 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #6759.

UBS Group first reported a position in TVRD in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.64M in Q4 2018. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • UBS Group held 50,454 shares of Tvardi Therapeutics worth $160K as of Q1 2026.
  • UBS Group bought 14,899 Tvardi Therapeutics shares in Q1 2026, an estimated $58.4K.
  • Tvardi Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6759 holding.
  • UBS Group first reported a position in Tvardi Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Tvardi Therapeutics position peaked at $2.64M in Q4 2018.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.